Inozyme Pharma clinical trials
Acquired by BioMarin Pharmaceutical, Jul 1, 2025 · source ↗
The registry lists 12 studies whose lead sponsor is Inozyme Pharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Before and after it joined BioMarin Pharmaceutical
- First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- 11
- First submitted after Inozyme Pharma became part of BioMarin Pharmaceutical
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Inozyme Pharma12 studies
Something wrong with this grouping? Tell us on the BioMarin Pharmaceutical page.
Studies
Recruiting first, then most recently updated. Showing 12 of 12. All BioMarin Pharmaceutical studies →
- ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 DeficiencyTerminatedNCT06462547Phase 2
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 DeficiencyTerminatedNCT05734196Phase 1
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXECompletedNCT05030831Phase 1/2
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 DeficiencyTerminatedNCT06046820Phase 3
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 DeficiencyTerminatedNCT06302439
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 DeficiencyTerminatedNCT07473973Phase 3
Sponsor listed in the registry: Inozyme Pharma · First submitted after Inozyme Pharma became part of BioMarin Pharmaceutical
- SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney DiseaseCompletedNCT06283589Phase 1
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- Natural History Study: ENPP1 Deficiency or the Early-Onset Form of ABCC6 DeficiencyCompletedNCT07745179
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 DeficiencyCompletedNCT05050669
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 DeficiencyWithdrawnNCT06739980Phase 2
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 DeficiencyCompletedNCT04686175Phase 1/2
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical
- Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 DeficiencyCompletedNCT04372446
Sponsor listed in the registry: Inozyme Pharma · First submitted before Inozyme Pharma became part of BioMarin Pharmaceutical